Testing a New Therapy for Trichotillomania
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00872742|
Recruitment Status : Unknown
Verified April 2014 by Douglas W. Woods, Texas A&M University.
Recruitment status was: Active, not recruiting
First Posted : March 31, 2009
Last Update Posted : April 10, 2014
|Condition or disease||Intervention/treatment||Phase|
|Trichotillomania||Behavioral: Acceptance enhanced behavior therapy (AEBT) Behavioral: Psychoeducation and supportive therapy (PST)||Phase 2|
Trichotillomania (TTM) is a disorder in which people compulsively pull out their own hair. Treatments for TTM sometimes do not have long-term effectiveness. Acceptance and commitment therapy (ACT) is a therapeutic approach thought to have longer lasting effects than standard cognitive behavioral therapy (CBT) approaches, because ACT focuses on accepting thoughts and behaviors as opposed to changing them. Previous research indicates that a combination of ACT and habit reversal behavioral therapy is more effective than no treatment. This study will test whether a combination of ACT and behavioral therapy, called acceptance enhanced behavioral therapy (AEBT), is more effective than the current standard treatment for TTM.
Participation in this study will last 12 weeks, and follow-up assessments will last for 6 months. At study entry, participants will complete a brief intelligence test and an in-person interview about their medical history, psychiatric history, and hair pulling. At their second visit, participants will have digital pictures taken of their hair-pulling sites and complete two computer tasks measuring their response inhibition and cognitive flexibility. After the second visit, participants will be randomly assigned to receive either AEBT or psychoeducation and supportive therapy (PST)—a standard treatment for TTM. Both treatments will involve ten 1-hour sessions completed over 12 weeks. Assessments of participants will occur after 6 weeks of treatment, at treatment completion, and after 6 months. These assessments will measure treatment effectiveness, based on several clinical scales and measures of TTM symptoms. Participants who receive PST during this study will be offered AEBT afterward.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||84 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Acceptance Enhanced Behavior Therapy for Trichotillomania|
|Study Start Date :||March 2009|
|Actual Primary Completion Date :||October 2013|
|Estimated Study Completion Date :||October 2014|
Participants will receive acceptance enhanced behavior therapy (AEBT) for trichotillomania (TTM).
Behavioral: Acceptance enhanced behavior therapy (AEBT)
Ten 1-hour sessions over 12 weeks, enhancing awareness of hair-pulling behavior and teaching strategies to deal with hair pulling
Active Comparator: 2
Participants will receive psychoeducation and supportive therapy (PST) for TTM.
Behavioral: Psychoeducation and supportive therapy (PST)
Ten 1-hour sessions over 12 weeks, teaching the participant about hair pulling and discussing how hair pulling affects those who do it
- Clinical Global Impressions-Improvement Scale [ Time Frame: Measured after 6 weeks, 12 weeks, and 6 months ]
- Massachusetts General Hospital Hairpulling Scale [ Time Frame: Measured at screening, baseline, and after 6 weeks, 12 weeks, and 6 months ]
- National Institute of Mental Health (NIMH) Trichotillomania Severity and Impairment Scales [ Time Frame: Measured at screening, baseline, and after 6 weeks, 12 weeks, and 6 months ]
- Clinical Global Impressions-Severity Scale [ Time Frame: Measured at screening, baseline, and after 6 weeks, 12 weeks, and 6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00872742
|United States, Texas|
|Texas A&M University|
|College Station, Texas, United States, 77845|
|Principal Investigator:||Douglas W. Woods, PhD||Texas A&M University|